Cantargia Year-end report January – December 2015

Cantargia AB (”Cantargia”) Year-end report for January – December 2015 is available on the company web-site (www.cantargia.com). An extract from the report is presented below.

Significant events in the fourth quarter

• European Patent Office (EPO) issued an officially approved patent for IL1RAP as target molecule for antibody therapy and leukemia diagnostics.
• EPO had issued an intention to grant for the Company’s application concerning IL1RAP as a target molecule for antibody therapy and diagnostics of several types of solid tumours.
• David Liberg took up the position as Vice President Cancer Research.
• Selection of primary indications - non-small cell lung cancer and pancreatic cancer.
• Data from the first toxicity study had been obtained and showed no indications of toxicity in clinically relevant doses.
• Warrants of series 2010:1 were exercised, resulting in a dilution of around 0.8 per cent for existing shareholders.

Significant events after the end of the period

• Approval from EPO of the patent application concerning IL1RAP as a target molecule for antibody therapy and diagnostics of several types of solid tumours.
• Approval in Australia for the patent application to use IL1RAP as target molecule for antibody treatment of haematological cancer diseases.

Financial information

Twelve months (1 Jan 2015 – 31 Dec 2015)

• Other operating revenue was KSEK 0 (0).
• Earnings after financial items were KSEK -17,190 (-8,370).
• Earnings per share were approximately SEK -1.27 (-0.62).
• The equity/assets ratio was approximately 89 (20) per cent.

Fourth quarter (1 Oct 2015 – 31 Dec 2015)

• Other operating revenue was KSEK 0 (0).
• Earnings after financial items were KSEK -5,003 (-2,547).
• Earnings per share were approximately SEK -0.37 (-0.19).

 Definitions

Earnings per share: Profit for the period divided by 13,505,874 shares as of 31 December 2015.
Equity/assets ratio: Equity divided by total capital.
Figures in parentheses refer to the same period in the previous year.

The Interim report 1, for January – March 2016 will be presented May 16, 2016. Previously announced date was May 11, 2016.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

---